T6A Biomarker for Detection of Bacterial Infection in Newborn Infants

Sponsor
Salzburger Landeskliniken
Study ID
NCT07670624
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Biomarker Discovery
  • Newborn Sepsis
  • Sepsis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.

Key Dates

First listed
Jun 26, 2026
Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Jan 31, 2029
Completion
Jan 31, 2029

Study Design

Enrollment
210 participants (estimated)

Arms

  • Arm: Patients
  • Arm: Controls

Primary Outcome Measure

Number of participants with Clinical Sepsis [ Time Frame: 12 Hours ]

Central Contacts

Related Studies